Literature DB >> 23972982

United States Food and Drug Administration approved oral kinase inhibitors for the treatment of malignancies.

Woondong Jeong1, James H Doroshow, Shivaani Kummar.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2013        PMID： 23972982      PMCID： PMC3761410          DOI： 10.1016/j.currproblcancer.2013.06.001

Source DB:  PubMed          Journal:  Curr Probl Cancer        ISSN： 0147-0272            Impact factor:   3.187


× No keyword cloud information.
  53 in total

1.  International Conference on Harmonisation; guidance on E14 Clinical Evaluation of QT/QTc Interval Prolongation and Proarrhythmic Potential for Non-Antiarrhythmic Drugs; availability. Notice.

Authors: 
Journal:  Fed Regist       Date:  2005-10-20

2.  Efficacy and safety of sunitinib in patients with advanced gastrointestinal stromal tumour after failure of imatinib: a randomised controlled trial.

Authors:  George D Demetri; Allan T van Oosterom; Christopher R Garrett; Martin E Blackstein; Manisha H Shah; Jaap Verweij; Grant McArthur; Ian R Judson; Michael C Heinrich; Jeffrey A Morgan; Jayesh Desai; Christopher D Fletcher; Suzanne George; Carlo L Bello; Xin Huang; Charles M Baum; Paolo G Casali
Journal:  Lancet       Date:  2006-10-14       Impact factor: 79.321

3.  Erlotinib in previously treated non-small-cell lung cancer.

Authors:  Frances A Shepherd; José Rodrigues Pereira; Tudor Ciuleanu; Eng Huat Tan; Vera Hirsh; Sumitra Thongprasert; Daniel Campos; Savitree Maoleekoonpiroj; Michael Smylie; Renato Martins; Maximiliano van Kooten; Mircea Dediu; Brian Findlay; Dongsheng Tu; Dianne Johnston; Andrea Bezjak; Gary Clark; Pedro Santabárbara; Lesley Seymour
Journal:  N Engl J Med       Date:  2005-07-14       Impact factor: 91.245

4.  Gefitinib plus best supportive care in previously treated patients with refractory advanced non-small-cell lung cancer: results from a randomised, placebo-controlled, multicentre study (Iressa Survival Evaluation in Lung Cancer).

Authors:  Nick Thatcher; Alex Chang; Purvish Parikh; José Rodrigues Pereira; Tudor Ciuleanu; Joachim von Pawel; Sumitra Thongprasert; Eng Huat Tan; Kristine Pemberton; Venice Archer; Kevin Carroll
Journal:  Lancet       Date:  2005 Oct 29-Nov 4       Impact factor: 79.321

5.  Lapatinib plus capecitabine for HER2-positive advanced breast cancer.

Authors:  Charles E Geyer; John Forster; Deborah Lindquist; Stephen Chan; C Gilles Romieu; Tadeusz Pienkowski; Agnieszka Jagiello-Gruszfeld; John Crown; Arlene Chan; Bella Kaufman; Dimosthenis Skarlos; Mario Campone; Neville Davidson; Mark Berger; Cristina Oliva; Stephen D Rubin; Steven Stein; David Cameron
Journal:  N Engl J Med       Date:  2006-12-28       Impact factor: 91.245

6.  Progression-free survival in gastrointestinal stromal tumours with high-dose imatinib: randomised trial.

Authors:  Jaap Verweij; Paolo G Casali; John Zalcberg; Axel LeCesne; Peter Reichardt; Jean-Yves Blay; Rolf Issels; Allan van Oosterom; Pancras C W Hogendoorn; Martine Van Glabbeke; Rossella Bertulli; Ian Judson
Journal:  Lancet       Date:  2004 Sep 25-Oct 1       Impact factor: 79.321

7.  Gefitinib in combination with paclitaxel and carboplatin in advanced non-small-cell lung cancer: a phase III trial--INTACT 2.

Authors:  Roy S Herbst; Giuseppe Giaccone; Joan H Schiller; Ronald B Natale; Vincent Miller; Christian Manegold; Giorgio Scagliotti; Rafael Rosell; Ira Oliff; James A Reeves; Michael K Wolf; Annetta D Krebs; Steven D Averbuch; Judith S Ochs; John Grous; Abderrahim Fandi; David H Johnson
Journal:  J Clin Oncol       Date:  2004-03-01       Impact factor: 44.544

8.  Gefitinib in combination with gemcitabine and cisplatin in advanced non-small-cell lung cancer: a phase III trial--INTACT 1.

Authors:  Giuseppe Giaccone; Roy S Herbst; Christian Manegold; Giorgio Scagliotti; Rafael Rosell; Vincent Miller; Ronald B Natale; Joan H Schiller; Joachim Von Pawel; Anna Pluzanska; Ulrich Gatzemeier; John Grous; Judith S Ochs; Steven D Averbuch; Michael K Wolf; Pamela Rennie; Abderrahim Fandi; David H Johnson
Journal:  J Clin Oncol       Date:  2004-03-01       Impact factor: 44.544

9.  American Thyroid Association guidelines for use of laboratory tests in thyroid disorders.

Authors:  M I Surks; I J Chopra; C N Mariash; J T Nicoloff; D H Solomon
Journal:  JAMA       Date:  1990-03-16       Impact factor: 56.272

10.  Imatinib compared with interferon and low-dose cytarabine for newly diagnosed chronic-phase chronic myeloid leukemia.

Authors:  Stephen G O'Brien; François Guilhot; Richard A Larson; Insa Gathmann; Michele Baccarani; Francisco Cervantes; Jan J Cornelissen; Thomas Fischer; Andreas Hochhaus; Timothy Hughes; Klaus Lechner; Johan L Nielsen; Philippe Rousselot; Josy Reiffers; Giuseppe Saglio; John Shepherd; Bengt Simonsson; Alois Gratwohl; John M Goldman; Hagop Kantarjian; Kerry Taylor; Gregor Verhoef; Ann E Bolton; Renaud Capdeville; Brian J Druker
Journal:  N Engl J Med       Date:  2003-03-13       Impact factor: 91.245
View more
  20 in total

Review 1.  Targeted Cancer Therapies and QT Interval Prolongation: Unveiling the Mechanisms Underlying Arrhythmic Complications and the Need for Risk Stratification Strategies.

Authors:  Rezarta Cuni; Iris Parrini; Riccardo Asteggiano; Maria Rosa Conte
Journal:  Clin Drug Investig       Date:  2017-02       Impact factor: 2.859

Review 2.  Progress in tumor-associated macrophage (TAM)-targeted therapeutics.

Authors:  Chayanon Ngambenjawong; Heather H Gustafson; Suzie H Pun
Journal:  Adv Drug Deliv Rev       Date:  2017-04-25       Impact factor: 15.470

Review 3.  Translational research in oncology--10 years of progress and future prospects.

Authors:  James H Doroshow; Shivaani Kummar
Journal:  Nat Rev Clin Oncol       Date:  2014-10-07       Impact factor: 66.675

4.  FOLFIRINOX-R study design: a phase I/II trial of FOLFIRINOX plus regorafenib as first line therapy in patients with unresectable RAS-mutated metastatic colorectal cancer.

Authors:  Antoine Adenis; Thibault Mazard; Julien Fraisse; Patrick Chalbos; Brice Pastor; Ludovic Evesque; Francois Ghiringhelli; Caroline Mollevi; Stéphanie Delaine; Marc Ychou
Journal:  BMC Cancer       Date:  2021-05-17       Impact factor: 4.430

5.  Histone deacetylase inhibitor resminostat in combination with sorafenib counteracts platelet-mediated pro-tumoral effects in hepatocellular carcinoma.

Authors:  Gundula Streubel; Sabine Schrepfer; Hannah Kallus; Ulrike Parnitzke; Tanja Wulff; Frank Hermann; Matthias Borgmann; Svetlana Hamm
Journal:  Sci Rep       Date:  2021-05-05       Impact factor: 4.379

Review 6.  Antiangiogenic Effect of Flavonoids and Chalcones: An Update.

Authors:  Ladislav Mirossay; Lenka Varinská; Ján Mojžiš
Journal:  Int J Mol Sci       Date:  2017-12-22       Impact factor: 5.923

Review 7.  Severe cutaneous adverse reactions induced by targeted anticancer therapies and immunotherapies.

Authors:  Chun-Bing Chen; Ming-Ying Wu; Chau Yee Ng; Chun-Wei Lu; Jennifer Wu; Pei-Han Kao; Chan-Keng Yang; Meng-Ting Peng; Chen-Yang Huang; Wen-Cheng Chang; Rosaline Chung-Yee Hui; Chih-Hsun Yang; Shun-Fa Yang; Wen-Hung Chung; Shih-Chi Su
Journal:  Cancer Manag Res       Date:  2018-05-17       Impact factor: 3.989

8.  β-Escin Effectively Modulates HUVECS Proliferation and Tube Formation.

Authors:  Lenka Varinská; Lenka Fáber; Martin Kello; Eva Petrovová; Ľudmila Balážová; Peter Solár; Matúš Čoma; Peter Urdzík; Ján Mojžiš; Emil Švajdlenka; Pavel Mučaji; Peter Gál
Journal:  Molecules       Date:  2018-01-17       Impact factor: 4.411

9.  Suppression of lung cancer progression by isoliquiritigenin through its metabolite 2, 4, 2', 4'-Tetrahydroxychalcone.

Authors:  Changliang Chen; Anitha K Shenoy; Ravi Padia; Dongdong Fang; Qing Jing; Ping Yang; Shi-Bing Su; Shuang Huang
Journal:  J Exp Clin Cancer Res       Date:  2018-10-03

10.  Ruxolitinib therapy for myelofibrosis in Austria : Consensus on therapy management.

Authors:  Maria-Theresa Krauth; Sonja Burgstaller; Veronika Buxhofer-Ausch; Günther Gastl; Klaus Geissler; Felix Keil; Peter Krippl; Thomas Melchardt; Andreas Petzer; Holger Rumpold; Thamer Sliwa; Stefan Wöhrer; Albert Wölfler; Heinz Gisslinger
Journal:  Wien Klin Wochenschr       Date:  2018-07-24       Impact factor: 1.704
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.